visceral adiposity raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-09. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
==== New Zealand ==== Since April 2024, pseudoephedrine has been classified as a restricted (pharmacist-only) drug in the Misuse of Drugs Act 1975 which allows the purchase of medicines containing pseudoephedrine from a pharmacist without a prescription. Pseudoephedrine, ephedrine, and any product containing these substances, e.g. cold and flu medicines, were first classified in October 2004 as Class C Part III (partially exempted) controlled drugs, due to being the principal ingredient in methamphetamine. New Zealand Customs and police officers continued to make large interceptions of precursor substances believed to be destined for methamphetamine production. On 9 October 2009, Prime Minister John Key announced pseudoephedrine-based cold and flu tablets would become prescription-only drugs and reclassified as a class B2 drug. The law was amended by The Misuse of Drugs Amendment Bill 2010, which passed in August 2011. In November 2023, the National-led coalition government announced that the sale of cold medication containing pseudoephedrine would be allowed (as part of the coalition agreement between the National and ACT parties).
=== University of Maryland === Although Fenselau and her second husband Robert Cotter both worked in mass spectrometry at Johns Hopkins, they chose to develop independent careers rather than a joint lab. "We felt that we could make twice as many contributions to science if we had two separate labs and evolved in our own ways that reflected our own skills and our own institutions." In 1987, Catherine Fenselau moved to the University of Maryland, Baltimore County (UMBC) to become chairperson of the Department of Chemistry and Biochemistry. She chose the university in part because she wanted greater opportunities for teaching. At UMBC she was one of the first faculty members involved in the Meyerhoff Scholarship Program, an initiative of UMBC president Freeman Hrabowski to attract minority undergraduate researchers. There, funding from the National Institutes of Health, the National Science Foundation, and others enabled Fenselau to establish a state-of-the-art mass spectrometry lab, the Structural Biochemistry Center (SBC). Equipment included a JEOL HX110/110 four-sector tandem mass spectrometer, a Hewlett-Packard quadrupole mass spectrometer with particle beam and Vestec electrospray ion sources, and 500 and 600 MHz NMR spectrometers. Research areas studied in the lab included biopolymer structure, ion thermochemistry, proton-binding entropies, glucuronide and glutathione conjugation, and possible mechanisms for acquired drug resistance. In June 1987, Fenselau oversaw the installation of a HighResMALDI Fourier transform mass spectrometer in her lab.
Antimicrobial peptides generally have a net positive charge, allowing them to interact with the negatively charged molecules exposed on bacteria and cancer cell surfaces, such as phospholipid phosphatidylserine, O-glycosylated mucins, sialylated gangliosides, and heparin sulfates. The mechanism of action of these peptides varies widely but can be simplified into two categories: membranolytic and non-membranolytic antimicrobial peptides. The disruption of membranes by membranolytic antimicrobial peptides can be described by four models:
Sources: en.wikipedia.org
=== Diagnostic and Statistical Manual === Initially considered a subject for further research exploration, binge eating disorder was first included in the Diagnostic and Statistical Manual of Mental Disorders (DSM) in 1994, proposed a feature of an eating disorder. In 2013, it gained formal recognition as a psychiatric condition in the DSM-5. Until 2013, binge eating disorder was categorized as an Eating Disorder Not Otherwise Specified, an umbrella category for eating disorders that don't fall under the categories for anorexia nervosa or bulimia nervosa. Before DSM-5, Eating Disorder Not Otherwise Specified, which included BED, was diagnosed more often than both anorexia nervosa and bulimia nervosa. Because it was not a recognized psychiatric disorder in the DSM until 2013, it has been difficult to obtain insurance reimbursement for treatments. The disorder now has its own category under DSM-5, which outlines the signs and symptoms that must be present to classify a person's behavior as binge eating disorder. Studies have confirmed the high predictive value of these criteria for diagnosing BED. One study found that the method for diagnosing BED is for a clinician who typically diagnose using the DSM-5 criteria or taking the Eating Disorder Examination. The Structured Clinical Interview for DSM (SCID-5) takes no more than 75 minutes to complete and has a systematic approach which follows the DSM-5 criteria. The Eating Disorder Examination is a semi-structured interview that identifies the frequency of binges and associated eating disorder features.
In June 2019, Pritzker signed into law Senate Bill 25, or the Reproductive Health Act. The act repealed the Illinois Abortion Law of 1975, which penalized doctors for performing abortions considered "unnecessary", and the "Partial-Birth Abortion Ban Act". The new bill ensured the "fundamental right to make autonomous decisions about one's own reproductive health", specifically the right to choose whether to carry a pregnancy to term or to terminate it, and denies a zygote, an embryo, or a fetus "independent rights under the law" of the State of Illinois. Pritzker encouraged other states that had passed restrictions on abortion to reconsider their positions and said that women from other states could access medical services in Illinois. After Dobbs v. Jackson overturned Roe v. Wade in 2022, Illinois became an abortion-access state for people in the South and Midwest whose states ban abortion, with 30% of abortions being for out-of-state residents. Abortions in Illinois increased by over 45% in the year after Roe was overturned, primarily due to patients' traveling from states with abortion bans. In 2024, Pritzker signed the Birth Equity Act, which required Illinois-based health insurance providers to cover abortion care without copayments or deductibles. On June 24, 2026, Pritzker signed the Reproductive Health Records Privacy Act, a law that protects those seeking abortions in Illinois by shielding digital medical records from out-of-state entities, effective July 1, 2027.
Hahn was shot in the back in October 1951 by a disgruntled inventor who wished to highlight the neglect of his ideas by mainstream scientists. Hahn was injured in a motor vehicle accident in 1952, and had a minor heart attack the following year. In 1962, he published a book, Vom Radiothor zur Uranspaltung (lit. 'From Radiothorium to Uranium Fission'). It was released in English in 1966 with the title Otto Hahn: A Scientific Autobiography, with an introduction by Glenn Seaborg. The success of this book may have prompted him to write another, fuller autobiography, Otto Hahn. Mein Leben, but before it could be published, he fractured one of the vertebrae in his neck while getting out of a car. He gradually became weaker and died in Göttingen on 28 July 1968. His wife Edith survived him by only a fortnight. He was buried in the Stadtfriedhof in Göttingen. The day after his death, the Max Planck Society published the following obituary notice:
Sources: en.wikipedia.org
==== Minor Alienizers ==== Lovelian Balance (ラブーリ星人バラン・スー, Rabūri Seijin Baran Sū): A giant non-humanoid alien from Planet Lovely who smuggled the Fan Crusher's control mechanism for Don Moyaida, who subsequently betrayed him. In a fit of rage, Balance takes a bus and its occupants hostage, but is easily defeated and arrested by Deka Blue, Green, Yellow, and Pink. Diamantian Don Moyaida (ディアマンテ星人ドン・モヤイダ, Diamante Seijin Don Moyaida): A diamond-themed criminal from Planet Diamante who is charged with infanticide, vehicular manslaughter, and the theft of terrestrial resources. He was originally believed to have died following a car chase with Ban in his combat vehicle-themed Kaijuki, Scarabader (スカラベーダー, Sukarabēdā), but Don Moyaida resurfaces on Earth disguised as a human to use his primary drill vehicle–like Kaijuki, Fan Crusher (ファンクラッシャー, Fan Kurasshā), to harvest the planet's resources and produce space jewelry as well as give Agent Abrella information on the Deka Base's Anubisium, the material used in its walls' construction. Don Moyaida succeeds in the latter task before he is deleted by Deka Red, while the Fan Crusher is destroyed by Dekaranger Robo. Don Moyaida is voiced by Takanori Kikuchi (菊池 隆則, Kikuchi Takanori), who also portrays his human form. Grorserian Hell Heaven (グローザ星人ヘルヘヴン, Gurōza Seijin Heru Hevun): A criminal and underling of Kevakia from Planet Grorser who is charged with kidnapping for profit-making and murder in Star-29.
TikTok has taken measures to remove and prevent access to content displaying the trend. Another TikTok trend known as the Kia Challenge involves users stealing certain models of Kia and Hyundai cars manufactured without immobilizers, which was a standard feature at the time, between 2010 and 2021. As of February 2023, it had resulted in at least 14 crashes and eight deaths according to the National Highway Traffic Safety Administration. In May, Kia and Hyundai settled a $200-million class-action lawsuit by agreeing to provide software updates to affected vehicles and over 26,000 steering wheel locks. In 2023, a trend emerged where streamers acted as if they were video-game characters following prompts from their viewers. On Douyin, the Chinese version of TikTok, some celebrities who had garnered large followings as of August 2019 include Dilraba Dilmurat, Angelababy, Luo Zhixiang, Ouyang Nana, and Pan Changjiang. In the 2022 FIFA World Cup, a Qatari teenage royal became an Internet celebrity after his angry expressions were recorded in Qatar's opening match loss to Ecuador; he amassed more than 15 million followers in less than a week after creating a Douyin account. On Douyin, viral memes and parodies of North Korea's tightly choreographed state propaganda such as "general's dance" or "You came from Dandong" amassed millions of views in 2024. The memes have also spilled offline. In Dandong, visitors have filmed themselves reenacting exaggerated greeting gestures toward the Yalu River, set to the same soundtracks popularized on Douyin.
CBC Digital Archives. "Chasing a Cure for Diabetes". Accessed 16 June 2008. Dr. Charles Best Secondary School. Accessed 16 June 2008. Ontario Plaques, "The Discovery of Insulin". Accessed 16 June 2008. Order of Canada citation (archived) University of Toronto. Banting and Best Department of Medical Research "Charles Herbert Best". Accessed 16 June 2008. "Rewriting Medical History: Charles Best and the Banting and Best Myth by Michael BLiss". Accessed 23 July 2011. Charles Best Papers (Archived 2016-03-03 at the Wayback Machine), Thomas Fisher Rare Book Library. Charles H. Best Foundation archival papers held at the University of Toronto Archives and Records Management Services
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.